Medtronic(MDT) Prnewswire·2025-01-13 07:00Adaptive Deep Brain Stimulation (aDBS) Technology - Adaptive deep brain stimulation (aDBS) represents a significant evolution in Parkinson's disease management by using real-time brain activity to dynamically adjust stimulation, offering patient-specific therapy [1] - BrainSense™ aDBS is the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation, approved in the EU and UK under CE Mark [6] - The technology enhances the ability to deliver personalized stimulation, adapting to an individual's unique brain signals both in clinical settings and daily life [7] Medtronic's Leadership in DBS Therapy - Medtronic is the originator of continuous deep brain stimulation (cDBS), a proven therapy for Parkinson's disease symptoms, and has served over 185,000 people in more than 70 countries since 1987 [3] - The company remains the first and only to offer a complete sensing-enabled DBS system, with BrainSense™ technology at the center of personalizing DBS therapy [9][10] - Medtronic's Percept™ DBS system with BrainSense™ technology records and analyzes brain signals, enabling therapies tailored to each patient's unique neurological patterns [9] Clinical Advancements and Studies - The largest and longest assessment of aDBS was conducted in both clinical and home settings, developed in collaboration with world-renowned neurologists and neurosurgeons [2] - The ADAPT-PD trial evaluates the safety and effectiveness of chronic dual- and single-threshold aDBS modes compared to cDBS, highlighting its potential in clinical practice [10] - BrainSense™ Electrode Identifier improves DBS programming by ensuring optimal initial contact selection in less time, leveraging local field potentials and alpha-beta activity [11] Market and Regulatory Developments - BrainSense™ aDBS and BrainSense™ Electrode Identifier will be available in Europe in early 2025, with Medtronic filing for U.S. FDA approval [12] - The CE Mark approval of BrainSense™ aDBS marks a critical advancement in Parkinson's disease treatment, offering new hope for patients and their families [11] Industry Impact and Patient Benefits - Parkinson's disease affects over 1.2 million patients in Europe and more than 10 million worldwide, significantly impacting mobility, speech, and daily life [8] - BrainSense™ aDBS allows patients to spend less time thinking about their disease, improving day-to-day disease management and broadening the transformative impact of DBS therapy [10][11]